Atara Biotherapeutics, Inc.ATRANASDAQ
Loading
Operating Expenses Over TimeContracting
Percentile Rank31
3Y CAGR-43.0%
5Y CAGR-0.2%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
-43.0%/yr
vs +9.8%/yr prior
5Y CAGR
-0.2%/yr
Recent deceleration
Acceleration
-52.8pp
Decelerating
Percentile
P31
Within normal range
vs 5Y Ago
1x
Modest growth
Streak
3 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $63.70M | -66.7% |
| 2024 | $191.37M | -30.6% |
| 2023 | $275.69M | -19.9% |
| 2022 | $344.09M | +336.7% |
| 2021 | $78.80M | +22.4% |
| 2020 | $64.40M | -78.2% |
| 2019 | $295.68M | +24.7% |
| 2018 | $237.11M | +95.1% |
| 2017 | $121.53M | +49.6% |
| 2016 | $81.24M | - |